Using MASL to Combat Oral Cancer

Summary

This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).

Timeline

Start

2021-01-29

Primary completion

2024-12-31

Completion

2025-05-15

Publications

• Results Yin AC, Holdcraft CJ, Helmig TJ, Brace EJ, Suster DI, Shienbaum AJ, Roden D, Kalyoussef E, Mir G, Capitle E, Baredes S, Shanti RM, Kaneko MK, Kato Y, Kobayashi H, Furusawa A, Fatahzadeh M, Goldberg GS. Effects of Maackia amurensis seed lectin (MASL) on OSCC cell morphology, PDPN expression, growth, and motility in a phase 1 clinical trial. J Cancer Res Clin Oncol. 2025 Jul 19;151(7):218. doi: 10.1007/s00432-025-06265-z.

Drugs

Indications